gdc

Lymphoma

Zynlonta First FDA-Approved CD19-Targeted Therapy for Large B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
In April 2021, the FDA approved Zynlonta (loncastuximab tesirine), the first CD19-directed antibody–drug conjugate, for the treatment of patients with relapsed or refractory large B-cell lymphoma.
Despite No Sex, We Were Never So Married
LymphomaPatient Stories
After putting off her neck pain for months, Susan Keller found that she had lymphoma, describing how her loving husband helped her change her attitude and persist through it all.
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
FDA Approvals, News & UpdatesLymphomaFollicular Lymphoma
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
FDA Approved Xalkori for Young Patients with Anaplastic Large-Cell Lymphoma and ALK Mutation
LymphomaBiomarkersFDA Approvals, News & Updates
In January 2021, the FDA approved a new indication for Xalkori (crizotinib), an oral ALK inhibitor, for the treatment of young patients who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma and ALK mutation. Xalkori was previously approved for metastatic lung cancer and ALK or ROS1 mutation.
Drugs for Lymphoma
Lymphoma
Here are the drugs and financial support services available to patients receiving treatment for Lymphoma.
FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
In July 2020, the FDA approved Monjuvi as a new treatment option for patients with diffuse large B-cell lymphoma whose disease progressed after receiving other therapies.
Tecartus First Gene Therapy FDA Approved for Patients with Mantle-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
The FDA approved Tecartus as the first gene therapy (or CAR T-cell therapy) for patients with mantle-cell lymphoma, a rare type of non-Hodgkin lymphoma, that progressed after previous therapies.
Yescarta Leads to Long-Term Responses in  Patients with Advanced Follicular Lymphoma or Marginal-Zone Lymphoma
Lymphoma
A total of 80% of patients with relapsed (coming back) or refractory (not responding to therapy) slow-growing (indolent) non-Hodgkin lymphoma (NHL)—including patients with follicular lymphoma or marginal-zone lymphoma (MZL)—achieved a complete response (no sign of cancer) to Yescarta (axicabtagene ciloleucel), an anti-CD19 CAR T-cell therapy.
Page 1 of 6
Results 1 - 10 of 56

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest